Truist Financial restated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Truist Financial currently has a $23.00 price objective on the stock.
Several other research firms have also commented on ROIV. Piper Sandler assumed coverage on Roivant Sciences in a research report on Friday, January 5th. They set an overweight rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Roivant Sciences in a report on Tuesday, December 12th. They set a buy rating and a $14.00 price target for the company. Wolfe Research began coverage on Roivant Sciences in a research note on Thursday, February 15th. They set an outperform rating and a $17.00 price objective for the company. HC Wainwright cut their target price on Roivant Sciences from $18.00 to $17.00 and set a buy rating on the stock in a research report on Wednesday, February 14th. Finally, Bank of America raised their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a neutral rating in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $16.50.
Get Our Latest Stock Report on Roivant Sciences
Roivant Sciences Stock Performance
NASDAQ:ROIV opened at $9.95 on Monday. Roivant Sciences has a fifty-two week low of $6.92 and a fifty-two week high of $13.24. The firm’s 50 day moving average is $10.75 and its two-hundred day moving average is $10.40. The company has a market cap of $8.02 billion, a P/E ratio of 1.91 and a beta of 1.37. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. The firm had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. Analysts expect that Roivant Sciences will post -1.36 EPS for the current year.
Insiders Place Their Bets
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 3,000,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $11.05, for a total transaction of $33,150,000.00. Following the completion of the transaction, the insider now directly owns 51,929,426 shares of the company’s stock, valued at approximately $573,820,157.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Vivek Ramaswamy sold 3,000,000 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $11.05, for a total transaction of $33,150,000.00. Following the transaction, the insider now owns 51,929,426 shares in the company, valued at $573,820,157.30. The disclosure for this sale can be found here. 4.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in ROIV. Citigroup Inc. boosted its holdings in Roivant Sciences by 45.6% in the third quarter. Citigroup Inc. now owns 326,431 shares of the company’s stock worth $3,813,000 after purchasing an additional 102,279 shares in the last quarter. Morgan Stanley raised its position in shares of Roivant Sciences by 48.7% during the third quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock valued at $225,560,000 after buying an additional 6,324,915 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Roivant Sciences by 18.4% in the third quarter. Deerfield Management Company L.P. Series C now owns 1,604,487 shares of the company’s stock valued at $18,740,000 after purchasing an additional 249,513 shares in the last quarter. Artia Global Partners LP increased its stake in Roivant Sciences by 422.5% in the second quarter. Artia Global Partners LP now owns 824,363 shares of the company’s stock valued at $8,310,000 after acquiring an additional 666,600 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Roivant Sciences in the 3rd quarter worth approximately $4,200,000. Institutional investors and hedge funds own 64.76% of the company’s stock.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Receive News & Ratings for Roivant Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roivant Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
/cloudfront-us-east-1.images.arcpublishing.com/pmn/X6WXZ45CTJGKRMHHJYBUZ2TAKA.jpg)
